Exuma Biotech Corp. Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Exuma Biotech Corp.'s estimated annual revenue is currently $6.2M per year.(i)
  • Exuma Biotech Corp.'s estimated revenue per employee is $155,000

Employee Data

  • Exuma Biotech Corp. has 40 Employees.(i)
  • Exuma Biotech Corp. grew their employee count by 21% last year.

Exuma Biotech Corp.'s People

NameTitleEmail/Phone
1
Chairman & CEOReveal Email/Phone
2
VP, IP Strategy & LicensingReveal Email/Phone
3
VP, Research and DevelopmentReveal Email/Phone
4
VP Alliance Oprs ShanghaiReveal Email/Phone
5
Director, North America Clinical OperationReveal Email/Phone
6
Senior Director ITReveal Email/Phone
7
Chief Financial OfficerReveal Email/Phone
8
Human Resources DirectorReveal Email/Phone
9
Chief Business OfficerReveal Email/Phone
10
Sr. Director, Global Quality Assurance & CMCReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$17.5M11314%N/AN/A
#2
$1.9M120%N/AN/A
#3
$1.1M70%N/AN/A
#4
$4.5M2921%N/AN/A
#5
$4.8M3111%N/AN/A
#6
$3.1M20N/AN/AN/A
#7
$0.8M50%N/AN/A
#8
$1.1M70%N/AN/A
#9
$2.6M176%N/AN/A
#10
$0.6M4-56%N/AN/A
Add Company

What Is Exuma Biotech Corp.?

EXUMA Biotech is a clinical-stage biotechnology company committed to bringing to market CAR-T therapies for the treatment of cancer. Founded in 2015, The company has rapidly built its core technologies and a growing global presence with operations in China (Shanghai and Shenzhen), Grand Cayman, and across the US with sites in West Palm Beach and San Diego.

keywords:N/A

N/A

Total Funding

40

Number of Employees

$6.2M

Revenue (est)

21%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Exuma Biotech Corp. News

2022-03-22 - EXUMA Biotech to Present Preclinical Data from its ...

EXUMA Biotech is a clinical-stage biotechnology company pioneering the discovery and development of novel cell and gene therapies for the...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$8.6M4018%N/A
#2
$10.4M408%N/A
#3
$8.6M4029%N/A
#4
$8.6M40-9%N/A
#5
$8.9M415%N/A